Suzhou Zelgen Biopharmaceuticals Co Ltd. Stock Analysis 688266.SS

Suzhou Zelgen Biopharmaceuticals Co., Ltd. engages in the innovation, research, development, manufacturing, and commercialization of new medications. The company is headquartered in Suzhou, Jiangsu and currently employs 1,055 full-time employees. The company went IPO on 2020-01-23. The firm focuses on the discovery, development and commercialization of innovative small molecule and biologic therapies, with a focus on oncology, autoimmune diseases and hemostasis/hematologic disorders. The firm has built a small molecule drug development platform, as well as bispecific/trispecific antibody and complex recombinant protein development platforms. The main products include donafenib tosylate tablets, gecacitinib hydrochloride tablets, recombinant human thrombin and human thyroid-stimulating hormone beta for injection. The firm operates in both the domestic market and overseas markets.